Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs

被引:0
作者
Liang, Shuang [1 ]
Wang, Xianying [1 ]
Zhu, Xiuqing [2 ,3 ]
机构
[1] Hebei Med Univ, Hosp 3, Dept Pharm, Shijiazhuang, Peoples R China
[2] Guangzhou Med Univ, Key Lab Neurogenet & Channelopathies, Guangdong Prov & Minist Educ China, Guangzhou, Peoples R China
[3] Guangzhou Med Univ, Affiliated Brain Hosp, Dept Pharm, Guangzhou, Peoples R China
关键词
NSAIDs; cardiovascular safety signals; FAERS; OpenVigil; 2.1; pharmacovigilance; pharmacodynamics; cyclooxygenase-1; cyclooxygenase-2; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COX-2; INHIBITORS; DISEASE; RISK;
D O I
10.3389/fphar.2024.1455212
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Aim Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat fever, pain, and inflammation. Concerns regarding their cardiovascular safety have been raised. However, the underlying mechanism behind these events remains unknown. We aim to investigate the cardiovascular safety signals and receptor mechanisms of NSAIDs, employing a comprehensive approach that integrates pharmacovigilance and pharmacodynamics.Methods This study utilized a pharmacovigilance-pharmacodynamic approach to evaluate the cardiovascular safety of NSAIDs and explore potential receptor mechanisms involved. Data were analyzed using the OpenVigil 2.1 web application, which grants access to the FDA Adverse Event Reporting System (FAERS) database, in conjunction with the BindingDB database, which provides target information on the pharmacodynamic properties of NSAIDs. Disproportionality analysis employing the Empirical Bayes Geometric Mean (EBGM) and Reporting Odds Ratio (ROR) methods was conducted to identify signals for reporting cardiovascular-related adverse drug events (ADEs) associated with 13 NSAIDs. This analysis encompassed three System Organ Classes (SOCs) associated with the cardiovascular system: blood and lymphatic system disorders, cardiac disorders, and vascular disorders. The primary targets were identified through the receptor-NSAID interaction network. Ordinary least squares (OLS) regression models explored the relationship between pharmacovigilance signals and receptor occupancy rate.Results A total of 201,231 reports of cardiovascular-related ADEs were identified among the 13 NSAIDs. Dizziness, anemia, and hypertension were the most frequently reported Preferred Terms (PTs). Overall, nimesulide and parecoxib exhibited the strongest signal strengths of ADEs at SOC levels related to the cardiovascular system. On the other hand, our data presented naproxen and diclofenac as drugs of comparatively low signal strength. Cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) were identified as central targets. OLS regression analysis revealed that the normalized occupancy rate for either COX-1 or COX-2 was significantly inversely correlated with the log-transformed signal measures for blood and lymphatic system disorders and vascular disorders, and positively correlated with cardiac disorders and vascular disorders, respectively. This suggests that higher COX-2 receptor occupancy is associated with an increased cardiovascular risk from NSAIDs.Conclusion Cardiovascular safety of NSAIDs may depend on pharmacodynamic properties, specifically, the percentage of the occupied cyclooxygenase isoenzymes. More studies are needed to explore these relations and improve the prescription process.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology
    Xie, Hao
    Xu, Qiang
    Zhao, Bin
    Wu, Wenming
    EXPERT OPINION ON DRUG SAFETY, 2025,
  • [22] Post-market safety profile and suicide/self-injury risk signals of dextromethorphan/bupropion: a real-world pharmacovigilance study
    Yuan, Lingjing
    He, Jianping
    Li, Xiangyu
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, : 1029 - 1041
  • [23] Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran)
    Valnet-Rabier, Marie -Blanche
    Tebacher, Martine
    Gautier, Sophie
    Micallef, Joelle
    Salvo, Francesco
    Pariente, Antoine
    Bagheri, Haleh
    THERAPIE, 2023, 78 (05): : 499 - 507
  • [24] Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
    Wang, Junwei
    Zhang, Aiwei
    Ye, Miaoyong
    Zhang, Cunming
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Automated Surveillance to Detect Postprocedure Safety Signals of Approved Cardiovascular Devices
    Resnic, Frederic S.
    Gross, Thomas P.
    Marinac-Dabic, Danica
    Loyo-Berrios, Nilsa
    Donnelly, Sharon
    Normand, Sharon-Lise T.
    Matheny, Michael E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (18): : 2019 - 2027
  • [26] Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data
    Frey, Connor
    Etminan, Mahyar
    ANTIBODIES, 2024, 13 (03)
  • [27] Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
    Giugliano, Dario
    De Nicola, Luca
    Maiorino, Maria Ida
    Bellastella, Giuseppe
    Esposito, Katherine
    DIABETES OBESITY & METABOLISM, 2019, 21 (08) : 1790 - 1800
  • [28] Neck circumference and cardiovascular outcomes: Insights from the Jackson Heart Study
    Pumill, Christopher A.
    Bush, Christopher G.
    Greiner, Melissa A.
    Hall, Michael E.
    Dunlay, Shannon M.
    Correa, Adolfo
    Curtis, Lesley H.
    Suzuki, Takeki
    Hardy, Chantelle
    Blackshear, Chad T.
    O'Brien, Emily C.
    Mentz, Robert J.
    AMERICAN HEART JOURNAL, 2019, 212 : 72 - 79
  • [29] Insights from circulating microRNAs in cardiovascular entities in turner syndrome patients
    Abu-Halima, Masood
    Oberhoffer, Felix Sebastian
    Abd El Rahman, Mohammed
    Jung, Anna-Maria
    Zemlin, Michael
    Rohrer, Tilman R.
    Kahraman, Mustafa
    Keller, Andreas
    Meese, Eckart
    Abdul-Khaliq, Hashim
    PLOS ONE, 2020, 15 (04):
  • [30] Hypertriglyceridaemia and cardiovascular mortality: insights from a large-scale study
    Patel, Hamza
    Grant, Jelani K.
    Martin, Seth S.
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (03) : 278 - 279